11 November 2025 Partnering with AI vendors can open doors for startups and small companies but it also brings serious risks. Experts at AI & IP Europe share key lessons on contracts, data ownership, ring-fencing, monitoring, and exit planning, as Marisa Woutersen reports.
11 November 2025
10 November 2025
6 November 2025
Latest Features
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
From setting a clear overall strategy to drafting high-quality claims, Christopher Wheeler and Gerald Murphy of Birch, Stewart, Kolasch & Birch explain how to reduce patent prosecution expenditure and obtain better IP protection.
Asia
Hui Zhuang of CCPIT Patent and Trademark Law Office discusses several strategies to increase the chance of pharmaceutical or food trademarks that include ingredients being registered.
More News
6 November 2025 Barley Snyder partner Sal Anastasi—woodworker, pilot, and now head of the AIPLA—speaks to WIPR about the urgent need for clarity in patent eligibility, and why collaboration and engagement are essential as the USPTO ushers in a period of rapid change.
4 November 2025 Growing clout, powerful remedies, and efficiency are making the UPC a game-changer in global litigation, according to LSPN Europe experts. Tom Phillips reports.
4 November 2025 Merck Serono has failed to convince a US appeals court to overturn a PTAB decision invalidating two dosing regimen patents for cladribine.
3 November 2025 With AI reshaping IP enforcement, the pharma giant’s IP head warns that only active guidance will stop the industry from lagging behind, reports Muireann Bolger.
1 November 2025 In his first public remarks since becoming the USPTO director, a bombastic John Squires promises an agency “in overdrive” that's doubling down on AI, reports Sarah Speight.
31 October 2025 Rising patent litigation over rare disease treatments highlights the success of the Hatch-Waxman and Orphan Drug Acts, says John Cox at Barnes & Thornburg.
30 October 2025 Private practitioners, in-house counsel and IP services from around the world converge in the US capital for the major event, from where Sarah Speight provides on-the-ground coverage.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox